BR112015025968A2 - poliplexos - Google Patents

poliplexos

Info

Publication number
BR112015025968A2
BR112015025968A2 BR112015025968A BR112015025968A BR112015025968A2 BR 112015025968 A2 BR112015025968 A2 BR 112015025968A2 BR 112015025968 A BR112015025968 A BR 112015025968A BR 112015025968 A BR112015025968 A BR 112015025968A BR 112015025968 A2 BR112015025968 A2 BR 112015025968A2
Authority
BR
Brazil
Prior art keywords
peptide
active agent
predetermined
polymer
polyplexes
Prior art date
Application number
BR112015025968A
Other languages
English (en)
Inventor
Connor Evans Brian
Brophy Colleen
Duvall Craig
Hocking Kyle
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of BR112015025968A2 publication Critical patent/BR112015025968A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/26—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)

Abstract

resumo “poliplexos” a presente revelação refere-se a compostos compreendendo (i) um agente ativo, em que o agente ativo inclui uma carga a um ph predeterminado, (ii) um polímero, em que o polímero inclui uma carga oposta do que a do agente ativo a um ph prédeterminado; e (iii) um poliplexo compreendendo o peptídeo e o polímero electrostaticamente ligado em conjunto a um ph predeterminado. em algumas formas de realização, o agente ativo é um peptídeo, tal como um peptídeo que compreende peptídeo inibitório mapkap quinasse ii, e, em algumas formas de realização o peptídeo inclui um peptídeo de penetração celular. em outras formas de realização, a invenção proporciona métodos para o tratamento de uma doença ou condição pela administração de uma composição de acordo com a presente invenção a um sujeito em necessidade do mesmo.
BR112015025968A 2013-04-11 2014-04-11 poliplexos BR112015025968A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361811078P 2013-04-11 2013-04-11
PCT/US2014/033873 WO2014169256A2 (en) 2013-04-11 2014-04-11 Polyplexes

Publications (1)

Publication Number Publication Date
BR112015025968A2 true BR112015025968A2 (pt) 2018-01-09

Family

ID=51690135

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015025968A BR112015025968A2 (pt) 2013-04-11 2014-04-11 poliplexos

Country Status (12)

Country Link
US (1) US10835549B2 (pt)
EP (1) EP2991616A4 (pt)
JP (1) JP2016518358A (pt)
KR (1) KR20150143639A (pt)
CN (1) CN105431134A (pt)
AU (1) AU2014250830A1 (pt)
BR (1) BR112015025968A2 (pt)
CA (1) CA2911315A1 (pt)
HK (1) HK1216152A1 (pt)
MX (1) MX2015014354A (pt)
RU (1) RU2015148055A (pt)
WO (1) WO2014169256A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201705559RA (en) 2015-01-08 2017-08-30 Moerae Matrix Inc Formulation of mk2 inhibitor peptides
CN104815333B (zh) * 2015-04-05 2017-10-31 北京工业大学 一种聚离子胶束纳米粒子的制备方法及其应用
US11147827B2 (en) 2016-08-05 2021-10-19 Vanderbilt University Conjugation of lipophilic albumin-binding moiety to RNA for improved carrier-free in vivo pharmacokinetics and gene silencing

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2445947A1 (en) * 2001-04-30 2002-11-07 Targeted Genetics Corporation Lipid-comprising drug delivery complexes and methods for their production
EP2138575B8 (en) * 2002-02-20 2013-07-24 Mersana Therapeutics, Inc. Conjugates comprising a biodegradable polymer and uses therefor
JP2006517790A (ja) * 2003-01-09 2006-08-03 インヴィトロジェン コーポレーション ポリペプチド−核酸複合体の細胞の送達および活性化
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US8741849B2 (en) * 2007-01-10 2014-06-03 Purdue Research Foundation Kinase inhibitors and uses thereof
US9271933B2 (en) 2007-11-27 2016-03-01 Rutgers, The State University Of New Jersey Graft copolymer polyelectrolyte complexes for drug delivery
WO2009133968A1 (ja) * 2008-04-30 2009-11-05 国立大学法人東京大学 電荷変換型三元系ポリプレックス
US20100150952A1 (en) * 2008-11-07 2010-06-17 University Of Washington pH-RESPONSIVE POLYMER CARRIER COMPOSITIONS FOR CYTOSOLIC PROTEIN DELIVERY
CA2744104C (en) * 2008-12-10 2017-07-18 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
EP2575855A4 (en) 2010-05-24 2014-03-12 Moerae Matrix Inc METHOD FOR TREATING OR PREVENTING VASCULAR GRAFT BREAKAGE
PT2970389T (pt) 2013-03-15 2020-10-21 Rhythm Pharmaceuticals Inc Composições farmacêuticas

Also Published As

Publication number Publication date
HK1216152A1 (zh) 2016-10-21
US10835549B2 (en) 2020-11-17
JP2016518358A (ja) 2016-06-23
WO2014169256A3 (en) 2014-12-11
CA2911315A1 (en) 2014-10-16
AU2014250830A1 (en) 2015-11-12
US20160058876A1 (en) 2016-03-03
CN105431134A (zh) 2016-03-23
EP2991616A4 (en) 2016-11-09
MX2015014354A (es) 2016-06-07
WO2014169256A2 (en) 2014-10-16
RU2015148055A (ru) 2017-05-16
KR20150143639A (ko) 2015-12-23
EP2991616A2 (en) 2016-03-09

Similar Documents

Publication Publication Date Title
PH12018501226A1 (en) Methods for treating huntingtons disease
CL2017001488A1 (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo
BR112015017405A2 (pt) composições que incluem agentes hidrofobizantes e estabilizantes e métodos para preparação e utilização das mesmas
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
EA201890641A3 (ru) Стимуляторы sgc
MX2017012512A (es) Moléculas que tienen utilidad plaguicida, e intermediarios, composiciones y procesos, relacionados con ellas.
BR112017023380A2 (pt) sistema, composição cosmética, métodos para tratamento de substratos queratinosos e para proteção e/ou alisamento da fibra do cabelo, kit multicompartimento, e, processo para alisamento do cabelo.
BR112015016997A2 (pt) composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama
BR112016000975A8 (pt) esteróides neuroativos, composições os compreendendo e uso dos mesmos
BR112015019794A8 (pt) Composto, composição farmacêutica, agonista do receptor de esfingosina-1-fosfato, e, uso de um composto
CL2017002082A1 (es) Nuevas proteínas especificas para pioverdina y pioquelina
BR112015020584A2 (pt) métodos para o tratamento de artrite psoriática usando apremilast
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
BR112018010381A2 (pt) composições para tratamento de cabelo, condicionadora de cabelo e para alteração da cor do cabelo, sistema para tratamento de cabelo, métodos para tratamento de cabelo e para alteração da cor do cabelo, e, kit de multicompartimentos.
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
BR112018013063A2 (pt) combinação terapêutica inibidora de bromodomínio e proteína extra-terminal
BR112015029462A8 (pt) Inibidores de quinase
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
BR112019004496A2 (pt) estabilizantes de mastócitos para tratamento de hipercitocinemia e infecção viral
BR112018077075A2 (pt) heterociclos de biarilmetila
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
WO2014153009A3 (en) Thiosaccharide mucolytic agents
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
BR112015018047A2 (pt) composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B06I Technical and formal requirements: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements